The concern of generic challenges has long loomed around copyright’s famous drug, Sildenafil, triggering questions about the future of connected drug portfolios. While initial times saw significant gains, the patent end has opened the door for cheaper substitutes, possibly lowering profitability and creating a real danger for shareholders looking